Skip to main content
Erschienen in: Der Anaesthesist 1/2006

01.01.2006 | Weiterbildung · Zertifizierte Fortbildung

Hepatorenales Syndrom

verfasst von: I. Kürer, A. Sommerer, G. Puhl, Prof. Dr. U. Kaisers, W. Boemke

Erschienen in: Die Anaesthesiologie | Ausgabe 1/2006

Einloggen, um Zugang zu erhalten

Zusammenfassung

Das hepatorenale Syndrom (HRS) ist definiert als das Auftreten einer Niereninsuffizienz bei fortgeschrittener Lebererkrankung nach Ausschluss anderer Ursachen einer renalen Funktionsstörung. Die Inzidenz des HRS beträgt bei Patienten mit Aszites 8%, die Gesamthäufigkeit des Nierenversagens liegt in der Endphase des Leberversagens bei 75%. Das Syndrom ist bei fortgeschrittener Lebererkrankung ein wesentlicher prognostischer Faktor. Die Pathogenese des HRS ist komplex, und ihre Aufklärung ist aktuell Gegenstand der Forschung.
Literatur
1.
Zurück zum Zitat Akriviadis E, Botla R, Briggs W et al. (2000) Pentoxifylline improves short-term survival in severe acute alcoholic hepatitis: a double-blind, placebo-controlled trial. Gastroenterology 119(6):1637–1648CrossRefPubMed Akriviadis E, Botla R, Briggs W et al. (2000) Pentoxifylline improves short-term survival in severe acute alcoholic hepatitis: a double-blind, placebo-controlled trial. Gastroenterology 119(6):1637–1648CrossRefPubMed
2.
Zurück zum Zitat Alessandria C, Ozdogan O, Guevara M et al. (2005) MELD score and clinical type predict prognosis in hepatorenal syndrome: relevance to liver transplantation. Hepatology 41(6):1282–1289CrossRefPubMed Alessandria C, Ozdogan O, Guevara M et al. (2005) MELD score and clinical type predict prognosis in hepatorenal syndrome: relevance to liver transplantation. Hepatology 41(6):1282–1289CrossRefPubMed
3.
Zurück zum Zitat Angeli P, Volpin R, Gerunda G et al. (1999) Reversal of type 1 hepatorenal syndrome with the administration of midodrine and octreotide. Hepatology 29(6):1690–1697CrossRefPubMed Angeli P, Volpin R, Gerunda G et al. (1999) Reversal of type 1 hepatorenal syndrome with the administration of midodrine and octreotide. Hepatology 29(6):1690–1697CrossRefPubMed
4.
Zurück zum Zitat Arroyo V, Gines P, Gerbes AL et al. (1996) Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis. International Ascites Club. Hepatology 23(1):164–176PubMed Arroyo V, Gines P, Gerbes AL et al. (1996) Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis. International Ascites Club. Hepatology 23(1):164–176PubMed
5.
Zurück zum Zitat Arroyo V, Guevara M, Gines P (2002) Hepatorenal syndrome in cirrhosis: pathogenesis and treatment. Gastroenterology 122(6):1658–1676CrossRefPubMed Arroyo V, Guevara M, Gines P (2002) Hepatorenal syndrome in cirrhosis: pathogenesis and treatment. Gastroenterology 122(6):1658–1676CrossRefPubMed
6.
Zurück zum Zitat Bacq Y, Gaudin C, Hadengue A et al. (1991) Systemic, splanchnic and renal hemodynamic effects of a dopaminergic dose of dopamine in patients with cirrhosis. Hepatology 14(3):483–487CrossRefPubMed Bacq Y, Gaudin C, Hadengue A et al. (1991) Systemic, splanchnic and renal hemodynamic effects of a dopaminergic dose of dopamine in patients with cirrhosis. Hepatology 14(3):483–487CrossRefPubMed
7.
Zurück zum Zitat Bellomo R, Chapman M, Finfer S et al. (2000) Low-dose dopamine in patients with early renal dysfunction: a placebo-controlled randomised trial. Australian and New Zealand Intensive Care Society (ANZICS) Clinical Trials Group. Lancet 356(9248):2139–2143CrossRefPubMed Bellomo R, Chapman M, Finfer S et al. (2000) Low-dose dopamine in patients with early renal dysfunction: a placebo-controlled randomised trial. Australian and New Zealand Intensive Care Society (ANZICS) Clinical Trials Group. Lancet 356(9248):2139–2143CrossRefPubMed
8.
Zurück zum Zitat Carstens J, Greisen J, Jensen KT et al. (1998) Renal effects of a urodilatin infusion in patients with liver cirrhosis, with and without ascites. J Am Soc Nephrol 9(8):1489–1498PubMed Carstens J, Greisen J, Jensen KT et al. (1998) Renal effects of a urodilatin infusion in patients with liver cirrhosis, with and without ascites. J Am Soc Nephrol 9(8):1489–1498PubMed
9.
Zurück zum Zitat Davenport A, Will EJ, Davison AM (1993) Effect of renal replacement therapy on patients with combined acute renal and fulminant hepatic failure. Kidney Int Suppl 41:245–251 Davenport A, Will EJ, Davison AM (1993) Effect of renal replacement therapy on patients with combined acute renal and fulminant hepatic failure. Kidney Int Suppl 41:245–251
10.
Zurück zum Zitat Epstein M, Goligorsky MS (1997) Endothelin and nitric oxide in hepatorenal syndrome: a balance reset. J Nephrol 10(3):120–135PubMed Epstein M, Goligorsky MS (1997) Endothelin and nitric oxide in hepatorenal syndrome: a balance reset. J Nephrol 10(3):120–135PubMed
11.
Zurück zum Zitat Evans LT, Kim WR, Poterucha JJ, Kamath PS (2003) Spontaneous bacterial peritonitis in asymptomatic outpatients with cirrhotic ascites. Hepatology 37(4):897–901CrossRefPubMed Evans LT, Kim WR, Poterucha JJ, Kamath PS (2003) Spontaneous bacterial peritonitis in asymptomatic outpatients with cirrhotic ascites. Hepatology 37(4):897–901CrossRefPubMed
12.
Zurück zum Zitat Forrest EH, Jones AL, Dillon JF et al. (1995) The effect of nitric oxide synthase inhibition on portal pressure and azygos blood flow in patients with cirrhosis. J Hepatol 23(3):254–258CrossRefPubMed Forrest EH, Jones AL, Dillon JF et al. (1995) The effect of nitric oxide synthase inhibition on portal pressure and azygos blood flow in patients with cirrhosis. J Hepatol 23(3):254–258CrossRefPubMed
13.
Zurück zum Zitat Gentilini P, Romanelli RG, La Villa G et al. (1993) Effects of low-dose captopril on renal hemodynamics and function in patients with cirrhosis of the liver. Gastroenterology 104(2):588–594PubMed Gentilini P, Romanelli RG, La Villa G et al. (1993) Effects of low-dose captopril on renal hemodynamics and function in patients with cirrhosis of the liver. Gastroenterology 104(2):588–594PubMed
14.
Zurück zum Zitat Gerbes AL, Gulberg V, Waggershauser T et al. (1998) Renal effects of transjugular intrahepatic portosystemic shunt in cirrhosis: comparison of patients with ascites, with refractory ascites, or without ascites. Hepatology 28(3):683–688CrossRefPubMed Gerbes AL, Gulberg V, Waggershauser T et al. (1998) Renal effects of transjugular intrahepatic portosystemic shunt in cirrhosis: comparison of patients with ascites, with refractory ascites, or without ascites. Hepatology 28(3):683–688CrossRefPubMed
15.
Zurück zum Zitat Gines P, Uriz J, Calahorra B et al. (2002) Transjugular intrahepatic portosystemic shunting versus paracentesis plus albumin for refractory ascites in cirrhosis. Gastroenterology 123(6):1839–1847CrossRefPubMed Gines P, Uriz J, Calahorra B et al. (2002) Transjugular intrahepatic portosystemic shunting versus paracentesis plus albumin for refractory ascites in cirrhosis. Gastroenterology 123(6):1839–1847CrossRefPubMed
16.
Zurück zum Zitat Gines P, Guevara M, Arroyo V, Rodes J (2003) Hepatorenal syndrome. Lancet 362(9398):1819–1827CrossRefPubMed Gines P, Guevara M, Arroyo V, Rodes J (2003) Hepatorenal syndrome. Lancet 362(9398):1819–1827CrossRefPubMed
17.
Zurück zum Zitat Gines P, Guevara M, Perez-Villa F (2004) Management of hepatorenal syndrome: another piece of the puzzle. Hepatology 40(1):16–18CrossRefPubMed Gines P, Guevara M, Perez-Villa F (2004) Management of hepatorenal syndrome: another piece of the puzzle. Hepatology 40(1):16–18CrossRefPubMed
18.
Zurück zum Zitat Gonwa TA, Wilkinson AH (1996) Liver transplanation and renal function: results in patients with and without hepatorenal syndrome. In: Epstein (ed) The kidney in liver disease, 4th edn. Hanley & Belfus, Philadelphia, pp 529–542 Gonwa TA, Wilkinson AH (1996) Liver transplanation and renal function: results in patients with and without hepatorenal syndrome. In: Epstein (ed) The kidney in liver disease, 4th edn. Hanley & Belfus, Philadelphia, pp 529–542
19.
20.
Zurück zum Zitat Gulberg V, Bilzer M, Gerbes AL (1999) Long-term therapy and retreatment of hepatorenal syndrome type 1 with ornipressin and dopamine. Hepatology 30(4):870–875CrossRefPubMed Gulberg V, Bilzer M, Gerbes AL (1999) Long-term therapy and retreatment of hepatorenal syndrome type 1 with ornipressin and dopamine. Hepatology 30(4):870–875CrossRefPubMed
21.
Zurück zum Zitat Hadengue A, Gadano A, Moreau R et al. (1998) Beneficial effects of the 2-day administration of terlipressin in patients with cirrhosis and hepatorenal syndrome. J Hepatol 29(4):565–570CrossRefPubMed Hadengue A, Gadano A, Moreau R et al. (1998) Beneficial effects of the 2-day administration of terlipressin in patients with cirrhosis and hepatorenal syndrome. J Hepatol 29(4):565–570CrossRefPubMed
22.
Zurück zum Zitat Henriksen JH, Ring-Larsen H (1994) Hepatorenal disorders: role of the sympathetic nervous system. Semin Liver Dis 14(1):35–43PubMed Henriksen JH, Ring-Larsen H (1994) Hepatorenal disorders: role of the sympathetic nervous system. Semin Liver Dis 14(1):35–43PubMed
23.
Zurück zum Zitat Holt S, Goodier D, Marley R et al. (1999) Improvement in renal function in hepatorenal syndrome with N-acetylcysteine. Lancet 353(9149):294–295CrossRefPubMed Holt S, Goodier D, Marley R et al. (1999) Improvement in renal function in hepatorenal syndrome with N-acetylcysteine. Lancet 353(9149):294–295CrossRefPubMed
24.
Zurück zum Zitat Jeyarajah DR, Gonwa TA, McBride M et al. (1997) Hepatorenal syndrome: combined liver kidney transplants versus isolated liver transplant. Transplantation 64(12):1760–1765CrossRefPubMed Jeyarajah DR, Gonwa TA, McBride M et al. (1997) Hepatorenal syndrome: combined liver kidney transplants versus isolated liver transplant. Transplantation 64(12):1760–1765CrossRefPubMed
25.
Zurück zum Zitat Koppel MH, Coburn JW, Mims MM et al. (1969) Transplantation of cadaveric kidneys from patients with hepatorenal syndrome. Evidence for the functionalnature of renal failure in advanced liver disease. N Engl J Med 280(25):1367–1371PubMed Koppel MH, Coburn JW, Mims MM et al. (1969) Transplantation of cadaveric kidneys from patients with hepatorenal syndrome. Evidence for the functionalnature of renal failure in advanced liver disease. N Engl J Med 280(25):1367–1371PubMed
26.
Zurück zum Zitat Klupp J, Kohler S, Pascher A, Neuhaus P (2005) Liver transplantation as ultimate tool to treat portal hypertension. Dig Dis 23(1):65–71CrossRefPubMed Klupp J, Kohler S, Pascher A, Neuhaus P (2005) Liver transplantation as ultimate tool to treat portal hypertension. Dig Dis 23(1):65–71CrossRefPubMed
27.
Zurück zum Zitat Martin PY, Gines P, Schrier RW (1998) Nitric oxide as a mediator of hemodynamic abnormalities and sodium and water retention in cirrhosis. N Engl J Med 339(8):533–541CrossRefPubMed Martin PY, Gines P, Schrier RW (1998) Nitric oxide as a mediator of hemodynamic abnormalities and sodium and water retention in cirrhosis. N Engl J Med 339(8):533–541CrossRefPubMed
28.
Zurück zum Zitat Mitzner SR, Stange J, Klammt S et al. (2000) Improvement of hepatorenal syndrome with extracorporeal albumin dialysis MARS: results of a prospective, randomized, controlled clinical trial. Liver Transpl 6(3):277–286CrossRefPubMed Mitzner SR, Stange J, Klammt S et al. (2000) Improvement of hepatorenal syndrome with extracorporeal albumin dialysis MARS: results of a prospective, randomized, controlled clinical trial. Liver Transpl 6(3):277–286CrossRefPubMed
29.
Zurück zum Zitat Moore K, Ward PS, Taylor GW, Williams R (1991) Systemic and renal production of thromboxane A2 and prostacyclin in decompensated liver disease and hepatorenal syndrome. Gastroenterology 100(4):1069–1077PubMed Moore K, Ward PS, Taylor GW, Williams R (1991) Systemic and renal production of thromboxane A2 and prostacyclin in decompensated liver disease and hepatorenal syndrome. Gastroenterology 100(4):1069–1077PubMed
30.
Zurück zum Zitat Moore K, Wendon J, Frazer M et al. (1992) Plasma endothelin immunoreactivity in liver disease and the hepatorenal syndrome. N Engl J Med 327(25):1774–1778PubMed Moore K, Wendon J, Frazer M et al. (1992) Plasma endothelin immunoreactivity in liver disease and the hepatorenal syndrome. N Engl J Med 327(25):1774–1778PubMed
31.
Zurück zum Zitat Moreau R, Durand F, Poynard T et al. (2002) Terlipressin in patients with cirrhosis and type 1 hepatorenal syndrome: a retrospective multicenter study. Gastroenterology 122(4):923–930CrossRefPubMed Moreau R, Durand F, Poynard T et al. (2002) Terlipressin in patients with cirrhosis and type 1 hepatorenal syndrome: a retrospective multicenter study. Gastroenterology 122(4):923–930CrossRefPubMed
32.
Zurück zum Zitat Ochs A, Rossle M, Haag K et al. (1995) The transjugular intrahepatic portosystemic stent-shunt procedure for refractory ascites. N Engl J Med 332(18):1192–1197CrossRefPubMed Ochs A, Rossle M, Haag K et al. (1995) The transjugular intrahepatic portosystemic stent-shunt procedure for refractory ascites. N Engl J Med 332(18):1192–1197CrossRefPubMed
33.
Zurück zum Zitat Ortega R, Gines P, Uriz J et al. (2002) Terlipressin therapy with and without albumin for patients with hepatorenal syndrome: results of a prospective, nonrandomized study. Hepatology 36(4 Pt 1):941–948PubMed Ortega R, Gines P, Uriz J et al. (2002) Terlipressin therapy with and without albumin for patients with hepatorenal syndrome: results of a prospective, nonrandomized study. Hepatology 36(4 Pt 1):941–948PubMed
34.
Zurück zum Zitat Persson PB, Ehmke H, Nafz B, Kirchheim HR (1990) Sympathetic modulation of renal autoregulation by carotid occlusion in conscious dogs. Am J Physiol 258(2 Pt 2):F364–370PubMed Persson PB, Ehmke H, Nafz B, Kirchheim HR (1990) Sympathetic modulation of renal autoregulation by carotid occlusion in conscious dogs. Am J Physiol 258(2 Pt 2):F364–370PubMed
35.
Zurück zum Zitat Restuccia T, Ortega R, Guevara M et al. (2004) Effects of treatment of hepatorenal syndrome before transplantation on posttransplantation outcome. A case-control study. J Hepatol 40(1):140–146CrossRefPubMed Restuccia T, Ortega R, Guevara M et al. (2004) Effects of treatment of hepatorenal syndrome before transplantation on posttransplantation outcome. A case-control study. J Hepatol 40(1):140–146CrossRefPubMed
36.
Zurück zum Zitat Rimola A, Garcia-Tsao G, Navasa M et al. (2000) Diagnosis, treatment and prophylaxis of spontaneous bacterial peritonitis: a consensus document. International Ascites Club. J Hepatol 32(1):142–153CrossRefPubMed Rimola A, Garcia-Tsao G, Navasa M et al. (2000) Diagnosis, treatment and prophylaxis of spontaneous bacterial peritonitis: a consensus document. International Ascites Club. J Hepatol 32(1):142–153CrossRefPubMed
37.
Zurück zum Zitat Rossle M, Ochs A, Gulberg V et al. (2000) A comparison of paracentesis and transjugular intrahepatic portosystemic shunting in patients with ascites. N Engl J Med 342(23):1701–1707CrossRefPubMed Rossle M, Ochs A, Gulberg V et al. (2000) A comparison of paracentesis and transjugular intrahepatic portosystemic shunting in patients with ascites. N Engl J Med 342(23):1701–1707CrossRefPubMed
38.
Zurück zum Zitat Runyon BA (1998) Management of adult patients with ascites caused by cirrhosis. Hepatology 27(1):264–272CrossRefPubMed Runyon BA (1998) Management of adult patients with ascites caused by cirrhosis. Hepatology 27(1):264–272CrossRefPubMed
39.
40.
Zurück zum Zitat Sauer IM, Gerlach JC (2002) Modular extracorporeal liver support. Artif Organs 26(8):703–706CrossRefPubMed Sauer IM, Gerlach JC (2002) Modular extracorporeal liver support. Artif Organs 26(8):703–706CrossRefPubMed
41.
Zurück zum Zitat Sauer IM, Goetz M, Steffen I et al. (2004) In vitro comparison of the molecular adsorbent recirculation system (MARS) and single-pass albumin dialysis (SPAD). Hepatology 39(5):1408–1414CrossRefPubMed Sauer IM, Goetz M, Steffen I et al. (2004) In vitro comparison of the molecular adsorbent recirculation system (MARS) and single-pass albumin dialysis (SPAD). Hepatology 39(5):1408–1414CrossRefPubMed
42.
Zurück zum Zitat Sort P, Navasa M, Arroyo V et al. (1999) Effect of intravenous albumin on renal impairment and mortality in patients with cirrhosis and spontaneous bacterial peritonitis. N Engl J Med 341(6):403–409CrossRefPubMed Sort P, Navasa M, Arroyo V et al. (1999) Effect of intravenous albumin on renal impairment and mortality in patients with cirrhosis and spontaneous bacterial peritonitis. N Engl J Med 341(6):403–409CrossRefPubMed
43.
Zurück zum Zitat Tepel M, van der Giet M, Schwarzfeld C et al. (2000) Prevention of radiographic-contrast-agent-induced reductions in renal function by acetylcysteine. N Engl J Med 343(3):180–184CrossRefPubMed Tepel M, van der Giet M, Schwarzfeld C et al. (2000) Prevention of radiographic-contrast-agent-induced reductions in renal function by acetylcysteine. N Engl J Med 343(3):180–184CrossRefPubMed
44.
Zurück zum Zitat Uriz J, Gines P, Cardenas A et al. (2000) Terlipressin plus albumin infusion: an effective and safe therapy of hepatorenal syndrome. J Hepatol 33(1):43–48CrossRefPubMed Uriz J, Gines P, Cardenas A et al. (2000) Terlipressin plus albumin infusion: an effective and safe therapy of hepatorenal syndrome. J Hepatol 33(1):43–48CrossRefPubMed
45.
Zurück zum Zitat Wilkinson SP, Williams R (1980) Renin-angiotensin-aldosterone system in cirrhosis. Gut 21(6):545–554PubMed Wilkinson SP, Williams R (1980) Renin-angiotensin-aldosterone system in cirrhosis. Gut 21(6):545–554PubMed
46.
Zurück zum Zitat Witzke O, Baumann M, Patschan D et al. (2004) Which patients benefit from hemodialysis therapy in hepatorenal syndrome? J Gastroenterol Hepatol 19(12):1369–1373CrossRefPubMed Witzke O, Baumann M, Patschan D et al. (2004) Which patients benefit from hemodialysis therapy in hepatorenal syndrome? J Gastroenterol Hepatol 19(12):1369–1373CrossRefPubMed
47.
Zurück zum Zitat Wong F, Pantea L, Sniderman K (2004) Midodrine, octreotide, albumin, and TIPS in selected patients with cirrhosis and type 1 hepatorenal syndrome. Hepatology 40(1):55–64CrossRefPubMed Wong F, Pantea L, Sniderman K (2004) Midodrine, octreotide, albumin, and TIPS in selected patients with cirrhosis and type 1 hepatorenal syndrome. Hepatology 40(1):55–64CrossRefPubMed
Metadaten
Titel
Hepatorenales Syndrom
verfasst von
I. Kürer
A. Sommerer
G. Puhl
Prof. Dr. U. Kaisers
W. Boemke
Publikationsdatum
01.01.2006
Verlag
Springer-Verlag
Erschienen in
Die Anaesthesiologie / Ausgabe 1/2006
Print ISSN: 2731-6858
Elektronische ISSN: 2731-6866
DOI
https://doi.org/10.1007/s00101-005-0957-4

Weitere Artikel der Ausgabe 1/2006

Der Anaesthesist 1/2006 Zur Ausgabe

Sind Frauen die fähigeren Ärzte?

30.04.2024 Gendermedizin Nachrichten

Patienten, die von Ärztinnen behandelt werden, dürfen offenbar auf bessere Therapieergebnisse hoffen als Patienten von Ärzten. Besonders gilt das offenbar für weibliche Kranke, wie eine Studie zeigt.

Akuter Schwindel: Wann lohnt sich eine MRT?

28.04.2024 Schwindel Nachrichten

Akuter Schwindel stellt oft eine diagnostische Herausforderung dar. Wie nützlich dabei eine MRT ist, hat eine Studie aus Finnland untersucht. Immerhin einer von sechs Patienten wurde mit akutem ischämischem Schlaganfall diagnostiziert.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Hinter dieser Appendizitis steckte ein Erreger

23.04.2024 Appendizitis Nachrichten

Schmerzen im Unterbauch, aber sonst nicht viel, was auf eine Appendizitis hindeutete: Ein junger Mann hatte Glück, dass trotzdem eine Laparoskopie mit Appendektomie durchgeführt und der Wurmfortsatz histologisch untersucht wurde.

Update AINS

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.